Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. M. Congiu is active.

Publication


Featured researches published by A. M. Congiu.


Journal of Clinical Oncology | 1998

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

Gino Santini; L Salvagno; P. Leoni; T. Chisesi; C. De Souza; Mario Roberto Sertoli; Alessandra Rubagotti; A. M. Congiu; R. Centurioni; A. Olivieri; L. Tedeschi; M Vespignani; Sandro Nati; Monica Soracco; A. Porcellini; A Contu; C Guarnaccia; N Pescosta; I. Majolino; Mauro Spriano; Renato Vimercati; Edoardo Rossi; G Zambaldi; L Mangoni; V. Rizzoli

PURPOSE The aim of this multicenter randomized study was to compare conventional therapy with conventional plus high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) as front-line treatment for poor-prognosis non-Hodgkins lymphoma (NHL). PATIENTS AND METHODS Between October 1991 and June 1995, 124 patients, aged 15 to 60 years, with diffuse intermediate- to high-grade NHL (Working Formulation criteria), stages II bulky (> or = 10 cm), III, or IV were enrolled. Sixty-one patients were randomized to receive etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (VACOP-B) for 12 weeks and cisplatin, cytarabine, and dexamethasone (DHAP) as a salvage regimen (arm A), and 63 to receive VACOP-B for 12 weeks plus HDT and ABMT (Arm B). RESULTS There was no significant difference in terms of complete remissions (CRS) in the two groups: 75% in arm A, and 73% in arm B. The median follow-up observation time was 42 months. The 6-year survival probability was 65% in both arms. There was no difference in disease-free survival (DFS) or progression-free survival (PFS) between the two groups. DFS was 60% and 80% (P = .1) and PFS was 48% and 60% (P = .4) for arms A and B, respectively. Procedure feasibility was the major problem. In arm B, 29% of enrolled patients did not undergo HDT and ABMT. A statistical improvement in terms of DFS (P = .008) and a favorable trend in terms of PFS (P = .08) for intermediate-/high- plus high-risk group patients assigned to HDT and ABMT was observed. CONCLUSION In this study, conventional chemotherapy followed by HDT and ABMT as front-line therapy seems no more successful than conventional treatment in terms of overall results. However, our results suggest that controlled studies of HDT plus ABMT should be proposed for higher risk patients.


Journal of Clinical Oncology | 1994

MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

Mario Roberto Sertoli; Gino Santini; Teodoro Chisesi; A. M. Congiu; A Rubagotti; A Contu; Luigi Salvagno; P Coser; A. Porcellini; M Vespignani

PURPOSE The aim of our study was to compare in a multicentric randomized trial two regimens widely used in the treatment of advanced-stage intermediate- to high-grade non-Hodgkins lymphoma and to assess whether a third-generation regimen (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin [MACOP-B]) was superior to a second-generation regimen (procarbazine, methotrexate with leucovorin, doxorubicin, cyclophosphamide, and etoposide [ProMACE-MOPP]). PATIENTS AND METHODS Between January 1987 and August 1991, 221 patients with diffuse intermediate- to high-grade non-Hodgkins lymphoma (Working Formulation groups F, G, H, and K), stage II bulky (> 10 cm), III, or IV, were randomized by the Non-Hodgkins Lymphoma Cooperative Study Group (NHLCSG) to receive ProMACE-MOPP for six cycles or MACOP-B for 12 weeks. Survival, progression-free survival, and disease-free survival were determined, and multivariate analysis of prognostic factors was performed. RESULTS In the two groups of patients, there was no significant difference in terms of complete remission (CR) rate (49.1% with ProMACE-MOPP and 52.3% with MACOP-B), 3-year overall survival rate (45.2% with PROMACE-MOPP and 52.3% with MACOP-B), and 3-year progression-free survival rate (36.4% with ProMACE-MOPP and 36.1% with MACOP-B). In terms of toxicity, no significantly greater toxicity occurred in either arm. Overall toxicity was acceptable. The most frequent side effects were grade II through IV leukopenia, infection, mucositis, and anemia. Treatment-related deaths were equally distributed. CONCLUSION No significant differences in terms of efficacy and/or toxicity between ProMACE-MOPP and MACOP-B are evident. These results are consistent with recent randomized trials showing that the new-generation aggressive regimens are no better than previous ones.


Brazilian Journal of Medical and Biological Research | 2000

Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study

C.A. De Souza; Gino Santini; G. Marino; Sandro Nati; A. M. Congiu; Afonso Celso Vigorito; Eugenio Damasio

Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75. 9%) affected by aggressive and 7 (24.1%) by indolent non-Hodgkins lymphoma (NHL), who were submitted to 58 infusions of amifostine and compared them with a historical group (33 patients) affected by aggressive NHL and treated with VACOP-B followed by HDCY. The most important results in favor of amifostine were the reduction of intensity of cardiac, pulmonary and hepatic toxicity, and a significant reduction of frequency and severity of mucositis (P = 0. 04). None of the 29 patients died in the protected group, while in the historical group 2/33 patients died because of cardiac or pulmonary toxicity and 2 patients stopped therapy due to toxicity. Amifostine did not prevent the aplastic phase following HDCY. PBPC collection and hematological recovery were adequate in both groups. The number of CFU-GM (colony-forming units-granulocyte/macrophage) colonies and mononuclear cells in the apheresis products was significantly higher in the amifostine group (P = 0.02 and 0.01, respectively). Side effects were mild and easily controlled. We conclude that amifostine protection should be useful in HDCY to protect normal tissues, with acceptable side effects.


Archive | 1991

Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission

Gino Santini; Paolo Coser; Teodoro Chisesi; Adolfo Porcellini; R. Sertoli; A. Contu; Orazio Vinante; A. M. Congiu; Angelo Michele Carella; T. D’Amico; Daniela Pierluigi; Edoardo Rossi; Daniele Scarpati; Vittorio Rizzoli

Thirty-six successive adult patients with lymphoblastic lymphoma entered a study of sequential chemotherapy consisting of an intensive LSA2-L2-type protocol to induce first complete remission. Eighteen patients in first CR (median age 22 years, range 15–51), underwent autologous bone marrow transplantation after receiving a conditioning regimen consisting of cyclophosphamide and total body irradiation. Of these 18 patients, 2 were in stage III and 16 in stage IV; 15 showed mediastinal and 9 bone marrow involvement at diagnosis. The transplant procedure was well tolerated and no treatment-induced deaths occurred. At this time, 14 out of 18 patients are alive and well between 1 and 60 months post transplant (median follow-up time 46 months) with an actuarial disease-free survival of 74%. This phase II study suggests that high-dose chemo-radiotherapy followed by autologous bone marrow transplantation may improve long-term disease-free survival in advanced stage adult lymphoblastic lymphoma.


Leukemia & Lymphoma | 1999

High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow.

Gino Santini; Carmino Antonio de Souza; A. M. Congiu; Sandro Nati; G. Marino; Monica Soracco; Sertoli Mr; Alessandra Rubagotti; Mauro Spriano; Franca Vassallo; Edoardo Rossi; Renato Vimercati; Giovanna Piaggio; Osvaldo Figari; Federica Benvenuto; Monica Abate; Mauro Truini; Jean Louis Ravetti; Iole Ribizzi; Eugenio Damasio

We report our experience of high-dose cyclophosphamide (HDCY) followed by high-dose therapy (HDT) and peripheral blood progenitor cell (PBPC) autografting in patients with diffuse, intermediate and high-grade non-Hodgkins lymphomas who have failed conventional treatment. From 1991 to 1996, 54 consecutive patients pre-treated with a median of two chemotherapy lines entered the study. Eighteen patients (33%) were still responders to conventional chemotherapy (sensitive relapse), and 20 patients (37%) were in partial response (PR) after chemotherapy (CT). Sixteen patients (30%) were resistant to conventional CT either at presentation (non responder) or in relapse (resistant relapse). Thirty-nine patients had bone marrow involved by disease and fifteen had an hypoplastic marrow following conventional treatment. Patients received HDCY (7gr/m2) and G-CSF or GM-CSF in order to collect PBPC. Median collected CD34+ cells was 12.3 x 10(6)/Kg (range 0.7-197). After HDT (BEAM or Melphalan + TBI) 50 patients underwent PBPC autografting. According to intention to treat, 44 (81%) of 54 patients achieved complete remission (CR) (50% after HDCY and 31% after HDT). Procedure related death occurred in 6 patients (11%), one after HDCY and 5 after autografting. Twenty-nine (66%) of 44 patients are still in CR, 7 to 63 months (median 27 months) after the procedure. Three-year probability of survival, disease-free survival and progression-free survival are 63%, 64% and 52% respectively. In conclusion, HDCY is an effective procedure not only in mobilizing PBPC, but also in reducing tumour burden. HDT with PBPC support may further improve the outcome in this category of high-risk non-Hodgkins lymphomas.


Leukemia & Lymphoma | 2001

Cemp, A Mitoxantrone Containing Combination, in the Treatment of Intermediate and High Grade Non-Hodgkin's Lymphoma: an Effective and Non Toxic Therapeutic Alternative for Adult and Elderly Patients: On behalf of Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG)

Teodoro Chisesi; P. Polistena; A. Contu; P. Coser; L. Indrizzi; P. Leoni; I. Majolino; Adolfo Porcellini; Luigi Salvagno; G. Zambaldi; Vittorio Rizzoli; A. M. Congiu; Gino Santini

Here we report the results of a randomised multicenter phase III clinical trial which assesses the therapeutic efficacy and tolerability of a chemotherapy protocol CEMP (cyclophosphamide, etoposide, mitoxantrone and prednisone) in adult and elderly patients with advanced intermediate and high-grade NHL. Between October 1991 and October 1995, 139 patients, aged 55 to 79 years, with diffuse intermediate and high-grade lymphoma, were enrolled. A considerable percentage of patients had clinically aggressive disease: 32.4% had systemic symptoms, 79% had stage III or IV disease, 33.8% had bone marrow involvement, 46% had splenic involvement and 42.5% had increased values of serum lactate dehydrogenate. Complete remission was achieved in 70 of the 139 patients (51.9%) and PR in 12 (16.6%) with an overall response of 68.5%. The overall response survival rate at 6 years was 39%, whereas DFS rate was 48.7% and PFS rate was 28.5%. At four years 49% of the patients were still in CR. Dividing the patients in two groups, under and over 65 years of age, we obtained the same results as far as overall response is concerned. No toxic deaths occured, neither cardiac, renal nor liver complications happened. CEMP regimen is an effective and safe protocol with good results in elderly people, well comparable to those achieved in younger ones.


Annals of Oncology | 2005

Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG

A. Olivieri; Gino Santini; Caterina Patti; Teodoro Chisesi; C.C. de Souza; Alessandra Rubagotti; S. Aversa; A. Billio; A. Porcellini; M. Candela; R. Centurioni; A. M. Congiu; M. Brunori; Sandro Nati; Mauro Spriano; Renato Vimercati; G. Marino; A Contu; L. Tedeschi; I. Majolino; Monica Crugnola; Mario Roberto Sertoli


Haematologica | 2001

Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma

Gino Santini; Sandro Nati; Mauro Spriano; Gallamini A; Pierluigi D; A. M. Congiu; Mauro Truini; Alessandra Rubagotti; Chisesi T; Renato Vimercati; Edoardo Rossi; Mario Roberto Sertoli; Mattei D; G. Marino; Marco Gobbi


Annals of Oncology | 1991

Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission Report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG)

Gino Santini; P. Coser; T. Chisesi; A. Porcellini; R. Sertoli; A. Contu; O. Vinante; A. M. Congiu; Angelo Michele Carella; T. D'Amico; D. Pierluigi; E. Rossi; D. Scarpati; V. Rizzoli


Leukemia & Lymphoma | 1997

Mobilization/Transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's lymphoma with marrow involvement

Gino Santini; A. M. Congiu; Sandro Nati; Letizia Canepa; Mauro Spriano; Chisesi T; Edoardo Rossi; Renato Vimercati; Sertoli Mr; Osvaldo Figari; Marco Gobbi; Giovanna Piaggio; Franca Vassallo; Federica Benvenuto; Monica Soracco; Maurizio Miglino; Jean Louis Ravetti; Mauro Truini

Collaboration


Dive into the A. M. Congiu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Angelo Michele Carella

Casa Sollievo della Sofferenza

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Teodoro Chisesi

Ca' Foscari University of Venice

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge